Meenhard Herlyn
Has grant
Professor, Director
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Targeting Aldehyde Dehydrogenase for Cancer Prevention
Open Date: 2020-04-15
Close Date: 2025-03-31
Grant: Close
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma
Open Date: 2019-12-13
Close Date: 2024-11-30
Grant: Close
Overcoming Resistance to Signaling and Immune
Open Date: 2019-10-01
Close Date: 2022-09-01
Grant: Close
Rational approaches to melanoma therapy
Open Date: 2017-09-30
Close Date: 2022-08-31
Grant: Close
SPORE in Skin Cancer
Open Date: 2014-09-16
Close Date: 2021-08-31
Articles (19)
Supplemental Table S1: Patient Characteristics by UGCG expression defined Risk Groups in the Learning Dataset; Supplemental Table S2: Patient Characteristics by UGCG expression defined Risk Groups in the Validation Dataset (Cirenajwis et al., 2015)
Year:
2025
Supplemental Figure S1: LAI remodels the lipidome of melanoma cells. Supplemental Figure S2: LAI induces UGCG, and UGCG inhibition augments DC661 cytotoxicity, and this effect is not seen by blocking cholesterol synthesis and key earlier steps of autophagy. Supplemental Figure S3: LAI increases the formation of GMM in cancer cells. Supplemental Figure S4: UGCG inhibition synergistically augments LAI induced cytotoxicity and abrogates GMM formation without elevating ceramide levels. Supplemental Figure S5: LAI induces UGCG-associated GMM formation in PDX cells, a combination of DC661 and eliglustat impairs tumor growth in a therapy-resistant PDX tumor model.
Year:
2025
Most advanced melanomas initially respond to targeted therapy but eventually relapse. Rather than acquiring new mutations, resistance is driven by drug-tolerant persister cells that enter a reversible drug-refractory state. We developed MeRLin, a high-resolution lineage tracing platform integrating cellular barcoding, single-cell transcriptomics, RNA fluorescence in situ hybridization (FISH), and computational analyses to track clonal and transcriptional dynamics in patient-derived melanoma models during prolonged therapy. Clonal dynamics revealed that persister subpopulations first responded to treatment but persisted and expanded during minimal residual disease, ultimately leading to tumor recurrence. Pre-treatment melanoma populations diversified into four conserved persister states characterized by stress-like, lipid metabolism, PI3K signaling, and extracellular matrix remodeling programs associated with adaptive resistance. Spatial transcriptomics showed the organization of these adaptive programs and a complex signaling network of autocrine and paracrine interactions among persister subpopulations. Barcoded RNA-FISH enabled spatial mapping of clonal identity and gene expression, revealing in situ co-localization of a dominant resistant clone with SLC2A1 expression. MeRLin provides a robust framework for dissecting cancer heterogeneity and identifying vulnerabilities in persister populations.
Year:
2025
Acral melanoma (AM) is an aggressive melanoma subtype with limited therapeutic options and poor outcomes. In non-European descent and admixed populations, like those residing in Latin America, AM accounts for a significant proportion of cutaneous melanoma cases. Here, we performed comprehensive genomic and functional profiling of AM from a uniquely diverse Brazilian cohort. Whole-exome and transcriptome sequencing revealed low mutation burden and predominance of copy number alterations, including high-amplitude focal amplifications termed hailstorms. These hailstorms frequently affected chromosomes 11, 5 and 22 and key oncogenes such as CCND1 , GAB2 , CDK4 , and TERT . The presence of hailstorms in the long arms of chromosomes 11 and 22 was associated with higher focal copy number burden and loss of DNA damage response genes ( ATM , CHEK1 ), suggesting a permissive genomic environment driving structural instability. To explore the unique genomic context of AM, we established a comprehensive collection of patient-derived xenograft (AM-PDX) models that faithfully retain the histopathological and genomic features of the original tumours. Functional exploration of AM-specific vulnerabilities through pharmacological and CRISPR/Cas9 knockout screenings identified strong sensitivity to targeting MAPK, CDK4/6, MDM2, and WEE1 pathways. Notably, the pan-RAS(ON) inhibitor RMC-7977 effectively reduced viability in NRAS -, KRAS -, and KIT -mutant AM cell lines. Finally, CRISPR screens revealed dependencies selectively essential in AM, including CRKL and SF3B4 , highlighting previously unrecognized vulnerabilities. Our findings emphasize the distinct biology of AM compared to other subtypes of melanoma, provide a valuable resource of models reflective of Latin American ancestry, and identify potential drivers and therapeutic targets.
Year:
2025
Resistance of BRAF -mutant melanomas to targeted therapy arises from the ability of cells to enter a persister state, evade treatment with relative dormancy, and repopulate the tumor when reactivated. A better understanding of the temporal dynamics and specific pathways leading into and out of the persister state is needed to identify strategies to prevent treatment failure. Using spatial transcriptomics in patient-derived xenograft models, we captured clonal lineage evolution during treatment. The persister state showed increased oxidative phosphorylation, decreased proliferation, and increased invasive capacity, with central-to-peripheral gradients. Phylogenetic tracing identified intrinsic and acquired resistance mechanisms (e.g., dual-specific phosphatases, reticulon-4, and cyclin-dependent kinase 2) and suggested specific temporal windows of potential therapeutic susceptibility. Deep learning–enabled analysis of histopathologic slides revealed morphologic features correlating with specific cell states, demonstrating that juxtaposition of transcriptomics and histologic data enabled identification of phenotypically distinct populations from using imaging data alone. In summary, this study defined state change and lineage selection during melanoma treatment with spatiotemporal resolution, elucidating how choice and timing of therapeutic agents will impact the ability to eradicate resistant clones. Significance: Tracking clonal progression during treatment uncovers conserved, global transcriptional changes and local clone–clone and spatial patterns underlying the emergence of resistance, providing insights into therapy-induced tumor evolution.
Year:
2025
Differentially expressed genes between time point 1 and time point 0 with significant corrected p-values in the resistant lineages (1, 2) but not in the sensitive lineages (0, 5, 8) , in the sensitive but not resistant, and in both sensitive and resistant (WM4007).
Year:
2025
Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited efficacy against solid tumors, even when the targeted antigens are well expressed. A better understanding of the underlying mechanisms of CAR T-cell therapy resistance in solid tumors is necessary to develop strategies to improve efficacy. Here we report that solid tumors release small extracellular vesicles (sEV) that carry both targeted tumor antigens and the immune checkpoint protein PD-L1. These sEVs acted as cell-free functional units to preferentially interact with cognate CAR T cells and efficiently inhibited their proliferation, migration, and function. In syngeneic mouse tumor models, blocking tumor sEV secretion not only boosted the infiltration and antitumor activity of CAR T cells but also improved endogenous antitumor immunity. These results suggest that solid tumors use sEVs as an active defense mechanism to resist CAR T cells and implicate tumor sEVs as a potential therapeutic target to optimize CAR T-cell therapy against solid tumors. Significance: Small extracellular vesicles secreted by solid tumors inhibit CAR T cells, which provide a molecular explanation for CAR T-cell resistance and suggests that strategies targeting exosome secretion may enhance CAR T-cell efficacy. See related commentary by Ortiz-Espinosa and Srivastava, p. 2637
Year:
2025
Drug tolerance and minimal residual disease (MRD) are likely to prelude acquired resistance to targeted therapy. Mechanisms that allow persister cells to survive in the presence of targeted therapy are being characterized but selective vulnerabilities for these subpopulations remain uncertain. We identified cellular inhibitor of apoptosis protein 2 (cIAP2) as being highly expressed in SOX10-deficient drug tolerant persister (DTP) melanoma cells. Here, we show that cIAP2 is sufficient to induce tolerance to MEK inhibitors, likely by decreasing the levels of cell death. Mechanistically, cIAP2 is upregulated at the transcript level in SOX10-deficient cells and the AP-1 complex protein, JUND, is required for its expression. Using a patient-derived xenograft model, we demonstrate that treatment with the cIAP1/2 inhibitor, birinapant, during the MRD phase delays the onset of resistance to BRAF inhibitor and MEK inhibitor combination therapy. Together, our data suggest that cIAP2 upregulation in SOX10-deficient subpopulations of melanoma cells induces drug tolerance to MAPK targeting agents and provides a rationale to test a novel therapeutical approach to target MRD.
Year:
2025
Melanoma is a common and aggressive cancer, with a rising incidence in most developed countries. Major discoveries in melanoma biology have been rapidly translated, allowing cures for some late-stage patients. Despite these advances, incomplete knowledge of genes and pathways that are gained or lost during melanogenesis prohibits cures for many patients. To identify gain-of-function and loss-of-function drivers of melanoma, we established a multi-omics cohort of melanoma patient-derived xenografts. By linking mutations with gene and protein expression, we characterize gain or loss-of-function of specific melanoma drivers in treatment refractory tumor models. We use multi-omics integration and structural-context representation to distinguish gain from loss of function variants, revealing new candidate melanoma genes and targets. This study provides a comprehensive resource of tumor models with the genetic, molecular and structural features of gain and loss of function melanoma drivers, allowing future development of better therapeutics for this devastating and heterogenous malignancy.
Year:
2024
Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited efficacy against solid tumors, even when the targeted antigens are well expressed. A better understanding of the underlying mechanisms of CAR T cell therapy resistance in solid tumors is necessary to develop strategies to improve efficacy. Here we report that solid tumors release small extracellular vesicles (sEVs) that carry both targeted tumor antigens and the immune checkpoint protein PD-L1. These sEVs acted as cell-free functional units to preferentially interact with cognate CAR T cells and efficiently inhibited their proliferation, migration, and function. In syngeneic mouse tumor models, blocking tumor sEV secretion not only boosted the infiltration and anti-tumor activity of CAR T cells but also improved endogenous anti-tumor immunity. These results suggest that solid tumors use sEVs as an active defense mechanism to resist CAR T cells and implicate tumor sEVs as a potential therapeutic target to optimize CAR T cell therapy against solid tumors.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (54)
Lawrence Rubinstein
Statistician
National Cancer Institute
Matthew H Bailey
Assistant Professor
Brigham Young University
Jose G. Trevino
Virginia Commonwealth University
Gordon Mills
Professor
Oregon Health & Science University
Michael A. Davies
-
Zebin Xiao
Professor
University of Pennsylvania
Sherri Davies
Senior Scientist
Washington University in St. Louis
Min Jin Ha
Assistant Professor
The University of Texas MD Anderson Cancer Center
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Monika Bhardwaj
Assistant Professor-II
Amity University Noida
Carl H. June
Professor
University of Pennsylvania
Peter Robinson
Professor for Medical Computer Science
The Jackson Laboratory for Genomic Medicine
Jeffrey Chuang
Jackson Laboratory
Xiaowei Xu
Professor
University of Pennsylvania
Shidan Wang
-
Serge Y. Fuchs
University of Pennsylvania
Junya Fujimoto
Professor and Chair
Hiroshima University Hospital
Inna Chervoneva
Thomas Jefferson University
Neil C. Sheppard
PI
University of Pennsylvania
Alana Welm
Chair
Huntsman Cancer Institute
Nicholas Mitsiades
Professor
University of California, Davis
Bryan Welm
Associate Professor
Huntsman Cancer Institute
Xuelin Huang
Professor
The University of Texas MD Anderson Cancer Center
Shunqiang Li
Associate Professor
Washington University in St. Louis
Jessie Villanueva
Associate Professor
The Wistar Institute
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
Ryan C. Fields
University of Rochester
Tara C. Mitchell
-
David Adams
Senior Group Leader (and Interim Programme Head)
Wellcome Sanger Institute
Luis G Carvajal‐Carmona
Professor
University of California, Davis
David W Speicher
Professor
The Wistar Institute
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Robert Mashl
Washington University in St. Louis
Chong-xian Pan
Professor
university of california davis medical center
Carol Bult
Professor and Knowlton Family Chair
Jackson Laboratory
Salma Kaochar
Assistant Professor
Baylor College of Medicine
Li Ding
Associate Professor
Washington University in Saint Louis School of Medicine
Carla Daniela Robles-Espinoza
Group Leader
National Autonomous University of Mexico
J. Chuck Harrell
Virginia Commonwealth University
Noam Auslander
Assistant professor
The Wistar Institute
Andrew E. Aplin
Thomas Jefferson University
Wei Guo
University of Pennsylvania
Michael Lewis
Baylor College of Medicine
Aaron Goldman
Member
The Wistar Institute
Qi Long
Professor
University of Pennsylvania
Olga Anczukow
Professor
Jackson Laboratory - Farmington
Ravi Amaravadi
Associate Professor, Clinician-Educator
University of Pennsylvania
Maria Gabriela Raso
Assistant Professor
The University of Texas MD Anderson Cancer Center
Qin Liu
Professor
The Wistar Institute
Soner Koc
GlaxoSmithKline Research and Development
Claudia Capparelli
Assistant Professor
Thomas Jefferson University
Guanghua Xiao
-
Yang Xie
Professor
University of Texas Southwestern Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.